Counterfeit Medicines At WHO: Off Board’s Agenda, Still On Secretariat’s
The issue of counterfeit and substandard medicines is again not on the agenda of the World Health Organization Executive Board meeting in January, though sources say member states are being consulted about the issue by the secretariat.

Daniele Dionisio argues some perspectives on health and IP might change now that controversial practices at the WTO, World Bank and IMF are increasingly under pressure, and that new government policy choices and actors on the world chessboard are emerging.